J&J Reports Financials, Details Debt Issuances

Ticker: JNJ · Form: 8-K · Filed: Oct 14, 2025 · CIK: 200406

Sentiment: neutral

Topics: debt-issuance, financing, financial-condition

TL;DR

J&J dropped an 8-K detailing a bunch of new debt notes across various maturities and rates.

AI Summary

Johnson & Johnson filed an 8-K on October 14, 2025, reporting on its financial condition and other events. The filing details various debt issuances, including notes due in 2028, 2029, 2032, 2033, 2035, 2036, 2037, 2044, 2045, and 2055, with coupon rates ranging from 1.150% to 3.700%.

Why It Matters

This filing provides insight into Johnson & Johnson's capital structure and financing activities, which can impact its financial flexibility and future investment capacity.

Risk Assessment

Risk Level: low — The filing is a standard disclosure of financial activities and does not indicate any immediate or significant risks to the company.

Key Numbers

Key Players & Entities

FAQ

What specific items are being reported under 'Results of Operations and Financial Condition'?

The filing primarily details various debt issuances with specific maturity dates and coupon rates, indicating financing activities rather than operational results.

What are the maturity dates for the notes issued by Johnson & Johnson?

The notes have maturity dates in November 2028, February 2029, November 2032, February 2033, 2035, November 2036, February 2037, November 2044, February 2045, and February 2055.

What is the range of coupon rates for the newly issued notes?

The coupon rates for the notes range from 1.150% to 3.700%.

What is the filing date of this 8-K report?

The 8-K report was filed on October 14, 2025.

What is the SIC code for Johnson & Johnson?

The Standard Industrial Classification (SIC) code for Johnson & Johnson is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2025-10-14 07:22:58

Key Financial Figures

Filing Documents

02 Results of operations and financial condition

Item 2.02 Results of operations and financial condition On October 14, 2025, Johnson & Johnson (the "Company") issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 28, 2025.

01 Other events

Item 8.01 Other events On October 14, 2025, the Company issued the attached press release (Exhibit 99.3) announcing its intent to separate the Company's Orthopaedics business.

01 Financial statements and exhibits

Item 9.01 Financial statements and exhibits (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated October 1 4 , 2025 for the period ended September 2 8 , 2025 99.2 Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal third quarter and nine months 99.3 Press Re lease dated October 14, 2025 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

Signatures

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 14, 2025 JOHNSON & JOHNSON (Registrant) By: /s/ Robert J. Decker, Jr. Robert J. Decker, Jr. Controller (Principal Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing